Latest From Oncimmune Ltd.
The growth potential of liquid biopsy diagnostics is drawing increasing attention, with several recent breakthrough device designations from the US FDA, big funding rounds, and major acquisitions all in play.
Biodesix is expanding its portfolio of lung cancer diagnostic tests and acquiring the US assets of UK company Oncimmune.
Oncimmune has expanded its offering in the US with the launch of a blood-based liver cancer test, the second product to emerge from its EarlyCDT platform.
While liquid biopsy is becoming routine for cancer treatment stratification and monitoring, using blood tests to screen for early cancer in asymptomatic people remains a tantalizing target. Some question how practical such a test could be but several companies are already en route - some further down the road than others - to achieve this goal. Illumina spin-out Grail is one of these companies and while it is not alone, in a field where size matters, it may have an advantage. This article delves deeper into how these different technologies work and when they could reach the market.
In Vitro Diagnostics
- Chemistry, Immunoassay
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Oncimmune Ltd.
- Senior Management
Adam Hill, PhD, CEO
Matthew Hall, CFO
Tariq Sethi, PhD, CSO
Matthew Luttrell, Chief Commercial Officer
- Contact Info
Phone: 115 8231869
Clinical Sciences Bldg. Nottingham Hosp.
Nottingham, NG5 1PB
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.